Cooley advised Ajax Therapeutics, a biopharmaceutical company developing next generation JAK inhibitors for patients with myeloproliferative neoplasms (MPNs), on its agreement to be acquired by Eli Lilly for up to $2.3 billion.
Ajax Therapeutics Acquired By Eli Lilly for Up to $2.3 Billion